Some medicines need particular monitoring because of their potential for harm. A reliable service identifies the monitoring required, arranges appropriate follow-up, reviews available results and escalates concerns. No process can guarantee that monitoring failures will never occur.
What counts as high-risk in primary care
Examples include lithium, methotrexate and other DMARDs, anticoagulants and amiodarone. Monitoring differs by medicine, indication, treatment stage and patient circumstances. It may involve blood tests, clinical observations, specialist assessment or review of ongoing need.
Use current medicine-specific guidance, the relevant shared-care arrangements and an individualised plan. A single blood-test interval or checklist is not suitable for every medicine and patient.
Where monitoring can fail
Risks include unclear responsibility after transfer of care, results that are available but not reviewed, missing results, non-attendance and changes in treatment that are not reflected in the recall system.
Review both the clinical circumstances and the process when a concern is found. Do not assume that an incident is solely an individual error, or solely a system problem, before understanding what happened.
Agreeing the work
The practice and service team need clear arrangements for identifying monitoring due, contacting patients, requesting tests, reviewing results and escalating concerns. Record who will take each action and how outstanding work will be followed up.
Our independent prescribers can make prescribing decisions within their competence and agreed protocols. Technicians can support suitable medicines and administrative work. Tasks requiring additional clinical assessment must go to an appropriate clinician.
What a monitoring system needs
- An accurate cohort: identify relevant patients and reconcile new starts, treatment changes and stops.
- Individual monitoring plans: record the checks required and when they are due.
- Recall and follow-up: support attendance and identify missing or unavailable results.
- Clinical review: review results and symptoms according to urgency, documenting decisions and escalation.
- Quality review: check outstanding actions and examine whether the process is working.
Search frequency, recall attempts and escalation times must be appropriate to risk and agreed locally. A fixed number of reminders must not delay an urgent clinical response.
Running a monitoring audit
Define the medicine, cohort, period and monitoring standard. Check the complete record, including relevant specialist information, before classifying monitoring as overdue. Record the findings, actions and unresolved issues, and plan re-audit.
Use your actual baseline. A claim about the percentage of patients overdue or the improvement after a year needs supporting records and a consistent denominator; it should not be presented as a universal benchmark.
Valproate and topiramate: reproductive-risk checks
MHRA guidance on valproate includes specialist prescribing restrictions and a Pregnancy Prevention Programme. The required reviews and risk acknowledgement forms differ for female and male patients and for new and existing treatment; check the requirements that apply to each patient.
For women and girls of childbearing potential, topiramate has had a Pregnancy Prevention Programme since 2024. This includes pregnancy-prevention measures and at least annual treatment review with a Risk Awareness Form.
Identify affected patients, check that required specialist reviews and forms are recorded, and follow up gaps according to clinical urgency and the agreed pathway. Missing documentation needs clinical follow-up; it is not an instruction to stop treatment abruptly.
When to seek support
Seek appropriate clinical help when concerns are identified, according to urgency. Do not wait for a set number of incidents before acting. Our high-risk drug monitoring service supports agreed monitoring work under clinical governance. Contact us to discuss the scope.
Primary references
NHS Specialist Pharmacy Service: lithium monitoring and individualising monitoring plans; NICE NG5 medicines optimisation; GPhC guidance for pharmacist prescribers.
Frequently asked questions
Do all high-risk medicines need the same monitoring?
No. Requirements depend on the medicine, indication, treatment stage and patient. Use current medicine-specific guidance and the agreed individual monitoring plan.
Can a monitoring system guarantee no failures?
No. A clear system supports safer prescribing and timely action, but missing results, non-attendance and other concerns still need active review and escalation.
Who does the work?
Agree who identifies monitoring, contacts patients, requests tests, reviews results and follows up concerns. Prescribing decisions must be taken by an appropriately qualified clinician within competence and the agreed protocol.
When should we act on a monitoring concern?
According to clinical urgency. Do not wait for a fixed number of incidents or reminder attempts when a patient may be at risk.
